Changes in the profiles of smokers seeking cessation treatment and in its effectiveness in Galicia (Spain) 2001-10 by Becoña, E. et al.
Becoña et al. BMC Public Health 2014, 14:613
http://www.biomedcentral.com/1471-2458/14/613RESEARCH ARTICLE Open AccessChanges in the profiles of smokers seeking
cessation treatment and in its effectiveness in
Galicia (Spain) 2001–10
Elisardo Becoña1*†, Ana López-Durán1†, Elena Fernández del Río1,2† and Úrsula Martínez1†Abstract
Background: In recent years, the prevalence of daily smokers has decreased in all developed countries due to a
great variety of factors. Despite this decrease, the effectiveness of clinical treatments has decreased and several
studies report a change in smokers’ characteristics. The purpose of the present study is to analyze the changes in
the characteristics of Spanish smokers who seek smoking cessation treatment between 2001 and 2010 and the
changes in the effectiveness of such treatment.
Methods: The sample was made up of 870 smokers who sought psychological treatment for giving up smoking
at the Smoking Cessation Unit in the Faculty of Psychology of the University of Santiago de Compostela (Spain)
during the period 2001 to 2010.
Results: Smokers in the 2006–2010 group, compared to those in the 2001–2005 group, were older, smoked fewer
cigarettes per day and of a brand with fewer mg/nicotine, had been smoking longer, were less motivated to give
up smoking, and had more antecedents of depression. Quit rates were validated by testing smokers' carbon
monoxide (CO) levels.
Percentages of abstinence were higher in the 2001–2005 group than in the 2006–2010 group (58.7% vs. 52.15
at the end of treatment, p = 0.05); 30.8% vs. 24.2% at 6 months follow-up, p = 0.031; 27.5% vs. 22% at 12 months
follow-up, p = 0.059). Although abstinence decreased more than 5% in the 2006–2010 group there were no differences
between the two groups in nicotine dependence. Those participants who did not assist to the follow-up were
considered smokers at pretreatment level.
Conclusions: In Spain there has been a qualitative change in the profile of the smokers seeking smoking cessation
treatment. Treatment effectiveness has decreased, and the variables predicting intervention outcome have changed.
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In recent years, the prevalence of daily smokers has
decreased in all developed countries [1,2]. In Spain,
according to the Spanish National Health Survey
(Encuesta Nacional de Salud), 31.7% of people of
18 years or older smoked every day in the year 2001,
whilst this percentage had fallen to 23.9% in 2012.
However, the percentage of occasional smokers has* Correspondence: elisardo.becona@usc.es
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unless otherwise stated.remained stable in the last decade [3]. More specifically,
according to a study conducted in Galicia, Spain, in 2005
[4], 25% of the population between 16 and 74 smoked
daily, with a slightly higher prevalence of smoking in men
than in women.
This significant decrease in the number of smokers
may be due to a range of factors. Irvin, Hendricks and
Brandon [5] consider that the main factors contributing
to a 25% fall in smoking in the USA between 1983 and
1998 were: increased concern about the negative health
consequences of smoking, the growth in limitations on
smoking in public places, and increased availability of
treatments for giving up smoking. In the same line,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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frequent in those contexts in which there are strong
restrictions on this activity, such as those in which the
price of cigarettes has increased significantly, or where
smoking has come to be considered non-normative
(through specific legislation).
With the aim of reducing the prevalence of smoking in
Spain, two legislative measures have been implemented
relatively recently (Ley 28/2005 and Ley 42/2010). Until
that moment, despite of the fact that many studies
conducted worldwide had demonstrated the risks that
smoke exposure had in health, smoking was allowed in
working and leisure places in Spain. Moreover, legislation
had focused only on the incorporation of health warnings
in tobacco related products. The entry in 2006 of the
Ley 28/2005 and in 2011 the Ley 48/2010 about health
measures against tobacco were based on various regulatory
aspects and on the promotion of programs and services
for tobacco treatment and prevention [7]. These laws
introduced the ban of tobacco advertising and promotion,
the reduction of tobacco retail outlets and smoking bans
in enclosed public spaces and workplaces.
After the introduction of these laws a positive impact
in Spanish people health was noted, as it significantly dimin-
ished smoking prevalence in adolescents; the number of
cigarettes smoked was decreased in people who continued
smoking; and the morbidity for acute myocardial infarction
reduced, an important indicator of the mortality attribut-
able to tobacco [8,9].
Catalina et al. [10] consider these measures to have
contributed significantly to the reduction in the number
of smokers and the prevalence of smoking. However,
according to Nebot and Fernández [11] this decrease in
the number of smokers – and even in the number of
cigarettes smoked per day in those who continue smok-
ing – are due to the falling trend in relation to this habit
observed before the introduction of this legislation. In
this vein, recent reviews [12] conclude that specific legal
prohibition with regard to smoking in public places
would have a greater effect on passive than on active
smoking, even though we cannot rule out the influence
of these types of measures in the reduction of smoking
among the general population.
In other countries, where this type of legislative meas-
ure has been applied for longer, there has been a more
detailed study of the changes in smokers’ characteristics
and in the effectiveness of smoking cessation treatments.
Thus, for example, Fagerström et al. [13] and Fagerström
and Furberg [14] analyzed the relationship between the
prevalence of smoking and nicotine dependence in a range
of countries. They concluded that as the number of
smokers decrease, the level of nicotine dependence among
those who continue to smoke increases (the so-called
“hardening hypothesis”). This concept of “hardening” isassociated with a decrease in the number of attempts to
give up and with smokers’ reduced capacity or maintain-
ing abstinence (due to their greater dependence). This
results in a need to use different strategies in relation
to the problem [15].
In this same way, Irvin and Brandon [16] point out
that as tobacco use decreases in the general population,
those who continue smoking are more difficult to treat,
and this is reflected in a reduction in effectiveness of
clinical treatments in recent years. Furthermore, these
researchers report a change in smokers’ characteristics,
greater use of other substances, higher levels of psycho-
pathology, lower educational levels, lower social status
and greater nicotine dependence.
The relation between the presence of psychopathology
and the effectiveness of smoking cessation treatment has
been widely studied. Piper et al. [17] and Schroeder and
Morris [18], for example, conclude that people with
problems of depression have more difficulty giving up
smoking. In line with this, the presence of psychopathology
should be considered when planning smoking cessation
treatment. A possible explanation for the poorer outcomes
in smokers with psychopathological problems, according to
de Leon, Becoña, Gurpegui, González-Pinto and Díaz [19],
is that these people would be more nicotine-dependent, this
being one of the variables most closely related to poorer
treatment results [20]. However, this view has been the
object of criticism. For example, Shiffman, Brockwell,
Pillitteri and Gitchell [21] hold that the relation between
nicotine dependence and abstinence takes the form of a
U. According to these authors, percentages of abstinence
tend to be higher in less dependent smokers, but also in
those with the greatest levels of dependence, to the extent
that in some cases it is the latter who show the highest
rates of treatment success. Smokers with moderate de-
pendence, on the other hand, tend to obtain poorer results
in smoking cessation treatments. A possible explanation
for this is that those with most dependence have greater
motivation for stopping smoking because they are subject
to more serious health problems caused by their smoking
[22], and health campaigns tend to be more especially
focused on them [15].
Specifically, in our own context, we have perceived a
significant increase in the number of people with ante-
cedents of depression (having current or past major
depressive episode) seeking smoking cessation treatment
[23] over the last decade. In this line, Schroeder and Morris
[18] point out that, although this type of population appar-
ently responds to smoking cessation treatments in the same
way as the general population, they tend to present higher
nicotine dependence, so that they require more intensive
interventions. So, these people with antecedents of depres-
sion may start experiencing such problems again on giving
up smoking [24].
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changes in the characteristics of Spanish smokers who
seek psychological treatment for smoking cessation in
the period 2001 to 2010 and to examine changes in the
effectiveness of such treatment.
Methods
Participants
The total sample was made up of people seeking psycho-
logical treatment for giving up smoking at the Smoking
Cessation Unit in the Faculty of Psychology of the Univer-
sity of Santiago de Compostela (Spain) during the period
2001 to 2010 (N = 870; 43.2% men and 56.8% women;
mean age = 40.64, SD = 10.69).
The smokers were selected according to the following
inclusion criteria: age 18 or over, voluntary participation
in the treatment programme, smoking a minimum of 10
cigarettes per day before the beginning of the treatment,
and filling out all the questionnaires in the pretreatment
assessment. Exclusion criteria were as follows: diagnostic
of a severe mental disorder (such as bipolar disorder,
psychotic disorder), concurrent cocaine or heroin depend-
ence, having received the same treatment programme or
another effective treatment for smoking cessation (nicotine
gum, nicotine patches, bupropion or varenicline) over the
last year, presenting a life-threatening pathology (e.g., recent
acute myocardial infarction, pneumothorax or Chronic
Obstructive Pulmonary Disease) that would require im-
mediate treatment, and failing to attend the first session
of the group treatment.
With the aim of comparing the evolution of smokers
seeking treatment for giving up smoking, we compared
two subsamples who received the treatment in the pe-
riods 2001–2005 (n = 465) and 2006–2010 (n = 405),
respectively.
Measures
Before starting the psychological treatment, all the smokers
filled out a questionnaire [25] designed to gather informa-
tion on both sociodemographic characteristics (e.g., gender,
age) and characteristics related to smoking (e.g., number of
cigarettes smoked per day, brand of cigarettes). This ques-
tionnaire also assesses the smoker’s stage of change at the
time of seeking treatment, according to Prochaska and
Diclemente’s [26] Transtheoretical Model of Change. This
allowed participants to be categorized as being in the
Precontemplation, Contemplation or Preparation stages of
change prior to beginning the smoking cessation treatment.
Likewise, nicotine dependence was assessed by means of
the Fagerström Test for Nicotine Dependence (FTND),
using a cut-off point of 6 or more for this variable [14].
As regards the assessment of depressive symptomatol-
ogy, we administered the MDE (Major Depressive Episode
Screener) [27]. This is an instrument for detecting a majordepressive episode in the past and/or in the last 15 days,
based on the DSM-IV diagnostic criteria. During the
interview, the smoker was also asked whether he or she
had received treatment for depression in the past and/
or recently.
Moreover, follow-up sessions were held at 6 and
12 months. During each follow-up session, questions were
asked concerning the status of the individual (smoker/
non-smoker) in that moment. The self-report abstinence
in all time periods was corroborated through the measure-
ment of expired breath carbon monoxide (CO). For this
purpose we used the Micro IV Smokerlyzer (Bedfont
Technical Instruments Ltd, Sittingbourne, Kent, UK).
This device takes samples of expired breath via a sensor,
indicating in particles per million (ppm) the participant’s
carbon monoxide in expired air (CO) level.
Procedure
The instruments described in the previous section were
administered in the initial assessment. All the smokers
gave written informed consent to take part in the study,
and the research was authorized by the Bioethics Com-
mittee of the University of Santiago de Compostela.
The psychological treatment applied (Programme for
giving up smoking, by Becoña [28,29]) is a cognitive-
behavioral treatment with 6 sessions, and it is applied in a
group format. Pharmacotherapy is not used. It comprises
the following components: treatment contract, self-report
and graphic representation of cigarette use, information
about tobacco, stimulus control, activities for avoiding
nicotine withdrawal syndrome, and physiological feedback
on cigarette use via the measurement of CO in each
session. Nicotine fading procedure is also used, changing
cigarette brands each week decreasing progressively their
intake of nicotine and tar. Finally, strategies for relapse
prevention are used (assertiveness training, problem-solving
strategies, change of erroneous beliefs, anxiety and anger
management, physical exercise, weight control and self-
reinforcement). Date of quitting is usually established
between the fourth and fifth session. The treatment
lasts 6 weeks (one session per week, of around one hour).
Smokers are treated in small groups of 2–8 people.
Assignment of the participants to groups took place
according to their own timetable and availability; neither
their sociodemographic nor their smoking characteristics
are taken into account in this respect. Those applying the
treatment were six psychologists with broad experience in
the treatment of smokers. We found no differences in
treatment outcomes as a function of the therapist assigned
to each group.
Once the treatment was over, the research team carried
out face-to-face follow-ups with the participants at 6 and
12 months. Both at the end of the smoking cessation treat-
ment and in the follow-up sessions we adopted the criteria
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point prevalence abstinence at the end of the treatment
(not having smoked in the last 24 hours, CO < 10 ppm)
and for continued abstinence at 6 and 12 months (not
having smoked, not even a puff, since the end of the treat-
ment programme, CO < 10 ppm).
In those cases in which it was not possible to locate the
participants for the follow-ups, they were considered
smokers at the same level (number in cigarettes and milli-
grammes of nicotine) as in the pretreatment assessment.
Statistical analysis
In order to determine the characteristics of the sample,
we carried out statistical analyses of a descriptive nature.
Likewise, for comparing the individuals treated in the two
periods adopted as references (2001–2005 and 2006–
2010), we used Pearson’s χ2 statistic for the categorical
variables and the Student t-test for the categorical with
numerical variables. In cases in which significant results
were found, we included the corresponding effect size
(Cramer’s V and Cohen’s d, respectively).
We also carried out a binary logistic regression ana-
lysis in each of the two groups of smokers to predict the
key variables in the treatment outcomes over the course
of 10 years. In the selection of the variables to form part
of the logistic regression model we took as a reference a
significance level of p < .05 in the univariate analysis. All
the statistical analyses in this study were carried out with
the IBM SPSS Statistics 20 package.
Results
Sociodemographic, smoking and psychopathological
characteristics
We compared the two groups of smokers attending
treatment over a 10-year period (Group 2001–2005 and
Group 2006–2010). The results reveal that smokers who
received treatment between 2006 and 2010 are older,
smoked fewer cigarettes/day of a brand with lower
nicotine content, have been smoking for less time (years)
and were less motivated to give up than those smokers
who attended treatment programmes between 2001 and
2005. We found no significant differences between the
two groups as regards nicotine dependence. As far as psy-
chological characteristics are concerned, in the 2006–2010
group there was a higher percentage of smokers who had
experienced a major depressive episode at some time in
their life and who had received treatment for depression
in the past and at the time of seeking treatment for giving
up smoking (see Table 1).
Evolution of the effectiveness of smoking cessation
treatment
When comparing treatment outcomes over 10 years, we
found a reduction in the effectiveness at the end of thetreatment (58.7% vs. 52.1%; χ2 (1) = 3.83; p = .05, Cramer’s
V = 0.07, p = .05) and at the 6-month follow-up (30.8%
vs. 24.2%; χ2 (1) = 4.64, p = .03; Cramer’s V = 0.07, p = .03).
At the 12-month follow-up, although it did not reach
statistical significance (27.5% vs. 22%; χ2 (1) = 3.56, p = .059),
the percentage of abstainers within the group treated
between 2001 and 2005 was also higher than that found
in the 2006–2010 group (see Figure 1).Depression and abstinence over the course of the treatment
The presence of depressive problems was related to lower
percentages of abstinence in the 2001–2005 group, both
at the end of the treatment and at the 6- and 12-month
follow-ups. In the 2006–2010 group there were only
differences at the end of the treatment, since smokers with
antecedents of depression obtained lower percentages of
abstinence at the end of treatment (see Table 2).Variables that predict the success of the smoking
cessation treatment
We conducted a logistic regression analysis separately for
the two groups and we found that the factors associated
with treatment success (i.e., abstinence) varied according
to the time point considered.
In the group of smokers treated between 2001 and
2005, the variables significantly associated with abstinence
at the end of the treatment were “being at the Preparation
stage of change” (OR = 1.79) and “smoking fewer than
25 cigarettes/day” (OR = 1.88). In contrast, “having experi-
enced a major depressive episode in the past” (OR = 0.59)
and “receiving treatment for depression at the time of
giving up smoking” (OR = 0.46) reduced the likelihood
of attaining abstinence. As regards the predictor variables
in the follow-ups, those participants with lower cigarette
consumption pretreatment, and who were not receiving
treatment for depression at that time were less likely to be
abstinent in the medium term. Specifically, we found
that at 6 months “smoking fewer than 25 cigarettes/
day” (OR = 1.59) and “being in treatment for depression
at the time of seeking treatment” (OR = 0.16) continued
to be predictors of abstinence. At the 12-month follow-up,
“being at the Preparation stage of change” (OR = 2.07) sig-
nificantly increased the likelihood of remaining abstinent,
whilst “being in treatment for depression at the time of
seeking treatment” (OR = 0.24) reduced such likelihood
(see Table 3).
With regard to the group of smokers treated between
2006 and 2010, we also found that “smoking fewer than
25 cigarettes/day” was a predictor variable associated with
abstinence both at the end of the treatment (OR = 2.81)
and at the 6-month (OR = 1.85) and 12-month follow-ups
(OR = 1.78). On the other hand, “having experienced a
major depressive episode in the past” was found to be
Table 1 Selected characteristics of smokers treated, by period
Group 2001–2005
(N = 465)
Group 2006–2010
(N = 405)
χ2/t Cramer’s V/
Cohen’s d
Sociodemographic characteristics
Gender (male) 43.0 43.5 0.02
Age (41 or over) 45.6 54.8 7.37** 0.09
Mean age (SD) 39.1 (10.5) 42.4 (10.6) −4.60*** 0.16
Marital status (married) 46.9 50.1 7.24
Characteristics related to smoking
N° of cigarettes/day (25 or more) 47.1 35.6 11.86** 0.12
Mean cigarettes/day (SD) 25.9 (10.9) 23.1 (9.3) 4.20*** 0.14
Milligrams of nicotine (0.8 mg or more) 88.2 81.0 8.68** 0.10
Mean milligrams of nicotine (SD) 0.8 (0.1) 0.7 (0.1) 6.49*** 0.23
Years smoking (20 years or more) 59.4 67.2 5.66* 0.08
Mean years smoking (SD) 21.6 (10.1) 24.4 (10.6) −3.96*** 0.13
Has tried to give up smoking in the last year 44.1 38.8 2.52
Stage of change (Preparation) 40.2 32.1 9.22* 0.10
Nicotine dependence (FTND≥ 6) 49.0 46.9 0.39
Mean nicotine dependence (SD) 5.24 (2.36) 5.24 (2.23) 0.01
Depression
MDE (past) 34.2 45.9 12.45*** 0.12
MDE (current) 8.2 8.6 0.06
Depressive disorder (past) 27.1 37.0 9.87** 0.11
Depressive disorder (current) 9.5 14.1 4.49* 0.07
Note: Means (SD) presented for continuous variables and percentages presented for numerical variables.
MDE =Major Depressive Episode; FTND = Fagerström Test for Nicotine Dependence.
*p < .05;**p < .01;***p < .001.
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ing at the end of the treatment (OR = 0.50) (Table 3).
Discussion
The aim of the present study was to analyze the changes
in the characteristics of Spanish smokers who received a
psychological treatment for smoking cessation and the
changes in the effectiveness of that treatment, between
the years 2001 and 2010. This period was important,
as it was when the Spanish government passed twoFigure 1 Abstinence at three stages of smoking treatment
by period.relevant legislative measures in relation to the control
of smoking.
The results reveal substantial differences between the
smokers seeking treatment for giving up smoking at the
Smoking Cessation Unit in the University of Santiago de
Compostela (Spain) over a 10-year period (2001–2010).
Those smokers who sought treatment in the period
2006–2010 were older, had been smoking for longer,
smoked fewer cigarettes and of brands with lower nico-
tine and tar content, were less motivated to give up
smoking, and had more depressive antecedents than
those who applied for the same treatment in the period
2001 to 2005. The decrease in the number of cigarettes
smoked daily in people who sought treatment is in line
with the fall reported by Nebot and Fernández [11] in
Spanish smokers. This decrease may be due, as sug-
gested by Warner [31] and Yong, Borland, Thrasher
and Thompson [32], to an increase of the social pressure
(e.g., rise in the price of cigarettes, specific legislation for
controlling consumption in certain spaces, etc.). It is not
surprising that the number of cigarettes smoked per day
has decreased if we take into account that it is forbidden
to smoke in locations where it was permitted previously,
Table 2 Percentages of abstinence at three stages of smoking treatment by depression history and period
Group 2001–2005 (N = 465) Group 2006–2010 (N = 405)
χ2 Cramer’s V χ2 Cramer’s V
End of the treatment
MDE (past) 47.2 (64.7) 13.27*** 0.17 44.1 (58.9) 8.85** 0.15
MDE (current) 31.6 (61.1) 12.56*** 0.16 40.0 (53.2) 2.25
Depressive disorder (past) 46.0 (63.4) 11.45** 0.16 44.0 (56.9) 6.26* 0.12
Depressive disorder (current) 31.8 (61.5) 14.50*** 0.18 50.9 (52.3) 0.04
6-month follow-up
MDE (past) 25.2 (33.7) 3.55 22.0 (26.0) 0.87
MDE (current) 13.2 (32.3) 6.02* 0.11 28.6 (23.8) 0.40
Depressive disorder (past) 25.4 (32.7) 2.33 19.3 (27.1) 3.07
Depressive disorder (current) 6.8 (33.3) 13.07*** 0.17 17.5 (25.3) 1.60
12-month follow-up
MDE (past) 20.1 (31.4) 6.63* 0.12 19.9 (23.7) 0.87
MDE (current) 7.9 (29.3) 7.99** 0.13 17.1 (22.4) 0.52
Depressive disorder (past) 23.0 (29.2) 1.76 18.0 (24.3) 2.19
Depressive disorder (current) 9.1 (29.5) 8.28** 0.13 15.8 (23.0) 1.48
Note: The percentage of abstinent individuals without antecedents of depression is shown in brackets.
MDE =Major Depressive Episode.
*p < .05;**p < .01;***p < .001.
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some indicators, as a decrease in tobacco sell figures, have
been a clear reflection of the reduction of tobacco use in
the Spanish population. However, although the number of
cigarettes smoked appears to have declined, the decrease
in the percentage of smokers is not that significant, which
can also be due to the economical crises or to the increase
of other types of tobacco, as can be roll-your-own ciga-
rettes, that has also been indicated by previous studies [33].
On the other hand, the reduction in the level of motiv-
ation does not agree with what was proposed by Hughes
[15], who points out that in the United States the
remaining smokers are more motivated to give up
smoking due to the growth of anti-smoking campaigns.
According to a previous study conducted in Galicia,
Spain [4], only 19% of the smokers were on the prepar-
ation stage, regardless of age or gender, and 44% of the
total daily smokers had made some serious attempts to
quit smoking. In contrast, the percentage of smokers of
the clinical population in the preparation stage, despite
having decreased in these ten years, they were significantly
older. The lower motivation on seeking treatment found
among the 2006–2010 group may be related to lower
self-efficacy as regards the ability to give up smoking in
a relatively short period of time (30 days). This low
self-efficacy could, in turn, be related to the increased
numbers of smokers with depressive problems in this
period. According to previous studies [34], smokers with
antecedents of depression would be highly motivated togive up smoking, but with low self-efficacy for achieving
that goal. Thus, the fact that many of the smokers who
come to treatment state that their intention to give up
smoking is more in the medium term (6 months) than the
short term (30 days) may be due to their low perceived
self-efficacy, rather than to lower motivation to change.
Therefore, it would be necessary to take into account both
the different stages of the motivational process in which
the smoker is situated at the time of the intervention [35]
and his or her perceived self-efficacy.
As regards nicotine dependence, we found no differ-
ences between the two groups. Despite the prevalence
of daily smokers in the general Spanish population has
decreased (31.7% in 2001 and 23.9% in 2012), we have
not found an increase in the level of nicotine dependence
among those who continue smoking and seek treatment.
This goes against the results reported in previous studies
carried out in other countries [12,13,16]. So this does
not confirm the “hardening hypothesis” among smokers
seeking treatment. Recent studies conducted in smokers
of the general population in Spain [36] or Italy [37] did
not found support for this hypothesis either.
About the evolution of the effectiveness of the treatment
for giving up smoking, the percentage of abstinence has
decreased by more than 5%. Previous research in coun-
tries like the United States had already indicated such a
trend [16]. In our case, the increased incidence of depres-
sion in the period 2006–2010 may explain the reduced
effectiveness of the treatment in that period. As Piper
Table 3 Predictors of abstinence at three stages of smoking treatment, by period
Ba Wald p value OR CI 95%
Group 2001-2005
End of the treatment
Stage of change (Preparation) 0.581 8.017 0.005 1.789 1.196-2.675
N° cig./day (<25 cig./day) 0.631 10.048 0.002 1.879 1.272-2.774
MDE past (yes) −0.521 5.488 0.019 0.594 0.384-0.918
Depressive disorder (current) (yes) −0.785 4.371 0.037 0.456 0.218-0.952
Constant 0.060 0.124 0.725 1.062
6-month follow-up
N° cig./day (<25 cig./day) 0.465 4.972 0.026 1.592 1.058-2.395
Depressive disorder (current) (yes) −1.822 8.942 0.003 0.162 0.049-0.534
Constant −0.962 35.605 0.000 0.382
12-month follow-up
Stage of change (Preparation) 0.728 11.730 0.001 2.071 1.365-3.142
Depressive disorder (current) (yes) −1.424 6.997 0.008 0.241 0.084-0.691
Constant −1.195 64.924 0.000 0.303
Group 2006-2010
End of the treatment
N° cig./day (<25 cig./day) 1.035 22.324 0.001 2.815 1.833-4.325
MDE (past) (yes) −0.689 10.820 0.001 0.502 0.333-0.757
Constant −0.265 1.906 0.167 0.767
6-month follow-up
N° cig./day (<25 cig./day) 0.614 5.596 0.018 1.848 1.111-3.075
Constant −1.560 50.293 0.000 0.210
12-month follow-up
N° cig./day (<25 cig./day) 0.577 4.622 0.032 1.781 1.052-3.013
Constant −1.660 53.275 0.000 0.190
Note. CI = confidence interval; FTND = Fagerström Test for Nicotine Dependence; ND = nicotine dependence; OR = odds ratio; MDE =Major Depressive Episode.
The category of reference is shown in brackets.
aThe groups were coded in the model as Smokers = 0 and Abstainers = 1.
Becoña et al. BMC Public Health 2014, 14:613 Page 7 of 9
http://www.biomedcentral.com/1471-2458/14/613et al. [17] and Schroeder and Morris [18] found, the
presence of depression reduces the likelihood of success
when a person tries to give up smoking. On the other
hand, we cannot support the argument of de Leon et al.
[19], since in our study the increase in psychopatho-
logical problems is not related to a rise in nicotine
dependence that could explain the poorer treatment
outcomes. Our results are in line with the view that
smokers with moderate dependence have more problems
for giving up smoking [21].
In relation to the variables that predict abstinence at
the end of the treatment and in the follow-ups, we also
found substantial differences. Whilst in the 2001–2005
group having antecedents of depression, a high rate of
cigarettes smoked per day and low motivation for change
predict lower likelihood of abstinence in any period, in the
2006–2010 group not having experienced a depressive
episode is associated only with giving up smoking at theend of the treatment, and not with abstinence at the
follow-ups. In this group, initial cigarette consumption is
the most important variable for predicting abstinence.
Therefore, having or not having depression is not anymore
an important variable for predicting the success of smok-
ing cessation treatment, at least in the long term. Perhaps
due to the high percentage of smokers with this problem
in the 2006–2010 group, depression has lost its predictive
value, so that number of cigarettes smoked becomes the
variable with the greatest weight for explaining the results
in the follow-ups. Given the notable increase in numbers
of smokers with depressive antecedents who wish to give
up smoking, we might suggest, in line with Borrelli’s [38]
proposal, the need to adapt smoking cessation treatment
for this type of smoker, modifying aspects such as the
mechanisms necessary for bringing about change, the way
of intervention or the intensity of the programme, with
the goal of improving treatment effectiveness.
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http://www.biomedcentral.com/1471-2458/14/613Thus, the results obtained over these 10 years indicate
that, in Spain, there has been a qualitative change in the
profile of the smoker seeking psychological smoking
cessation treatment (fewer cigarettes smoked, less mo-
tivation for change, and greater presence of depressive
antecedents), but we have not found changes in nicotine
dependence. Moreover, the effectiveness of smoking cessa-
tion treatment has decreased and there has been a signi-
ficant change in the variables that predict intervention
outcomes.
The present study has several limitations. First of all,
the results obtained cannot be extrapolated to smokers in
the general population, as smokers who seek specialized
treatment for giving up the habit tend to be qualitatively
different from those who do not [39,40]. Moreover, those
studies that have reviewed the evolution of smokers’ char-
acteristics have revealed different outcomes, as regards
nicotine dependence, for example, according to whether
the smokers in question are from the general population
or clinical population [15]. Secondly, it might be advisable
to assess the evolution of smokers’ dependence with other
instruments, such as the NDSS-S (Nicotine Dependence
Syndrome Scale-Short) [41] or the DSM criteria. Finally,
we only took into account psychopathological anteced-
ents related to depression. Various studies have stressed
the need to take account of other types of disorder,
such as anxiety disorders, mainly because of their high
prevalence [42].
To summarize, over the last decade we have seen a
significant fall in the prevalence of smokers in the gen-
eral population. At the same time, however, as found in
the present study, there has been a substantial change
in the characteristics of smokers who seek specialized
treatments for giving up smoking (and not always in
the same line as in countries other than Spain) and a
decrease in the effectiveness of such treatments. We con-
sider it necessary to continue making progress toward
improving interventions designed to address the serious
health problem of smoking, adapting ourselves to the
new profiles and demands of the population.Conclusions
There are important changes in the characteristics of
smokers who seek smoking cessation treatment:
1. Smokers in the 2006–2010 group are older, smoke
fewer cigarettes/day and of a brand with fewer mg/
nicotine, have been smoking for longer, are less
motivated, and have more depressive antecedents
than those in the 2001–2005 group.
2. In contrast to what has been found in other
countries, we found no changes with regard to level
of nicotine dependence between the two groups.3. There has been a reduction in treatment
effectiveness: percentage of abstinence decreased by
more than 5% in the 2006–2010 group.
4. The variables predicting intervention outcome have
also changed: in the 2001–2005 group those which
are significant are number of cigarettes/day
pretreatment, level of motivation and problems of
depression. In the 2006–2010 group, depression is
only significant at the end of the treatment, and the
most significant variable is number of cigarettes/day
pretreatment.
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